HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Gene Editing

Background:

• Cancer immunotherapies targeting immune checkpoints (IC) show promise but have limited efficacy in many patients.
• The immune checkpoint HLA-G is abnormally expressed in various cancers, creating a tolerogenic tumor microenvironment.
• Novel therapeutic targets and approaches are needed to overcome resistance to current immunotherapies.

Purpose of the Study:

• To investigate the efficacy of CRISPR/Cas9 gene editing for downregulating HLA-G expression in cancer cell lines.
• To assess the impact of HLA-G downregulation on immune cell response in vitro.
• To explore the potential of HLA-G targeted gene editing as a novel cancer immunotherapy.

Main Methods:

• CRISPR/Cas9 gene editing was employed to target HLA-G expression in renal cell carcinoma (RCC7) and choriocarcinoma (JEG-3) cell lines.
• Specific sgRNA/Cas9 plasmids targeting HLA-G exons 1 and 2 were utilized for gene editing.
• The degree of HLA-G downregulation, including complete silencing, was analyzed.
• In vitro immune cell responses were compared between HLA-G-edited and wild-type tumor cells.

Main Results:

• Successful downregulation of HLA-G expression was achieved in both RCC7 and JEG-3 cell lines, with varying degrees of success including complete silencing.
• HLA-G-negative (HLA-G-) cells elicited a significantly higher in vitro immune cell response compared to HLA-G-positive (HLA-G+) wild-type cells.
• This study provides the first demonstration of HLA-G downregulation using gene editing technology.

Conclusions:

• CRISPR/Cas9-mediated gene editing is an effective method for downregulating HLA-G expression in cancer cells.
• Reducing HLA-G expression enhances anti-tumor immune responses in vitro.
• Targeting HLA-G via gene editing represents a promising first step towards developing novel immunotherapeutic strategies for cancer treatment.